Nogo receptor 1 (RTN4R) as a candidate gene for schizophrenia: Analysis using human and mouse genetic approaches

PLoS ONE

Volumn 2, Issue 11, 2007, Pages

  Hsu, Ruby ^a   Woodroffe, Abigail ^b   Lai, Wen Sung ^c   Cook, Melloni N ^d   Mukai, Jun ^c   Dunning, Jonathan P ^d   Swanson, Douglas J ^e   Roos, J Louw ^f   Abecasis, Gonçalo R ^b   Karayiorgou, Maria ^c   Gogos, Joseph A ^a,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c The University of Memphis ^*  (United States)

^d University of Memphis   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NOGO RECEPTOR 1; MYELIN PROTEIN; PROTEIN NOGO; RTN4R PROTEIN, HUMAN; UNCLASSIFIED DRUG;

AFRICA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CHROMOSOME 22Q; CHROMOSOME ANALYSIS; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DNA POLYMORPHISM; EXON; FEMALE; GENE DELETION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; LOCOMOTION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PERINATAL PERIOD; PHENOTYPIC VARIATION; PROTEIN DEFICIENCY; PROTEIN FUNCTION; SCHIZOPHRENIA; SEQUENCE ANALYSIS; TASK PERFORMANCE; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; GENETICS; MOLECULAR GENETICS; MOUSE MUTANT; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALIA;

AMINO ACID SEQUENCE; ANIMALS; BEHAVIOR, ANIMAL; HUMANS; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; MYELIN PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CELL SURFACE; SCHIZOPHRENIA; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 43349106822     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001234     Document Type: Article

References (78)

1. David S, Aguayo AJ (1981) Axonal elongation into peripheral nervous system "bridges" after central nervous system injury in adult rats. Science 214: 931-933.
2. Domeniconi M, Cao Z, Spencer T, Sivasankaran R, Wang K, et al. (2002) Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron 35: 283-290.
3. Liu BP, Fournier A, GrandPre T, Strittmatter SM (2002) Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor. Science 297: 1190-1193.
4. Wang KC, Koprivica V, Kim JA, Sivasankaran R, Guo Y, et al. (2002) Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 417: 941-944.
5. Mi S, Lee X, Shao Z, Thill G, Ji B, et al. (2004) LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci 7: 221-228.
6. Park JB, Yiu G, Kaneko S, Wang J, Chang J, et al. (2005) A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors. Neuron 45: 345-351.
7. Shao Z, Browning JL, Lee X, Scott ML, Shulga-Morskaya S, et al. (2005) TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron 45: 353-359.
8. Fournier AE, GrandPre T, Strittmatter SM (2001) Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 409: 341-346.
9. Botto LD, May K, Fernhoff PM, Correa A, Coleman K, et al. (2003) A population-based study of the 22q11.2 deletion: phenotype, incidence, and contributuion to major birth defects in the population. Pediatrics 112: 101-107.
10. Morrow B, Goldberg R, Carlson C, Gupta RD, Sirotkin H, et al. (1995) Molecular definition of the 22q11.2 deletions in velo-cardio-facial syndromes. Amer J Hum Genet 56: 1391-1403.
11. Antshel KM, Kates WR, Roizen N, Fremont W, Shprintzen RJ (2005) 22q11.2 deletion syndrome: genetics, neuroanatomy and cognitive/behavioral features. Child Neuropsych 11: 5-19.
12. Sobin C, Kiley-Brabeck K , Daniels S, Khuri J, Taylor L, et al. (2005) Neuropsychological characteristics of children with the 22q11.2 deletion syndrome: a descriptive analysis. Child Neuropsychol 11: 39-53.
13. Woodin M, Wang PP, Aleman D, McDonald-McGinn D, Zackai E, et al. (2001) Neuropsychological profile of chilren and adolescents with the 22q11.2 microdeletion. Genet Med 3: 34-39.
14. Bearden CE, Woodin MF, Wang PP, Moss E, McDonald-McGinn D, et al. (2001) The neurocognitive phenotype of the 22q11.2 deletion syndrome: selective deficit in visual-spatial memory. J Clin Exp Neuropsychol 23: 447-464.
15. Simon TJ, Ding L, Bish JP, McDonald-McGinn DM, Zackai EH, et al. (2005) Volumetric, connective, and morphologic changes in the brains of children with chromosome 22q11.2 deletion syndrome: an integrative study. Neuroimage 25: 169-180.
16. van Amelsvoort T, Daly E, Robertson D, Suckling J, Ng V, et al. (2001) Structural brain abnormalities associated with deletion at chromosome 22q11.2. Brit J of Psych 178: 412-419.
17. Pulver AE, Nestadt G, Goldberg R, Shprintzen RJ, Lamacz M, et al. (1994) Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. J Nerv Ment Dis 182: 476-478.
18. Murphy KC, Jones LA, Owen MJ (1999) High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 56: 940-945.
19. Karayiorgou M, Morris MA, Morrow B, Shprintzen RJ, Goldberg R, et al. (1995) Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11.2. Proc Natl Acad Sci USA 92: 7612-7616.
20. Sobin C, Kiley-Brabeck K, Karayiorgou M (2005) Lower prepulse inhibition in children with the 22q11.2 deletion syndrome. Am J Psychiatry 162: 1090-1099.
21. Liu H, Heath SC, Sobin C, Roos JL, Galke BL, et al. (2002) Genetic variation at the 22q11.2 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci USA 99: 3717-3722.
22. Liu H, Abecasis GR, Heath SC, Knowles A, Demars S, et al. (2002) Genetic variation in the 22q11.2 locus and susceptibility to schizophrenia. Proc Natl Acad Sci USA 99: 16859-16864.
23. Mukai J, Liu H, Burt RA, Swor DE, Lai WS, et al. (2004) Evidence that the gene encoding ZDHHC8 contributes to the risk of schizophrenia. Nat Genet 36: 725-731.
24. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, Lev-Lehman E, et al. (2002) A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 71: 1296-1302.
25. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, et al. (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98: 6917-6922.
26. Paterlini M, Zakharenko SS, Lai WS, Qin J, Zhang H, et al. (2005) Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci 8: 1586-1594.
27. Raux G, Bumsel E, Hecketsweiler B, van Amelsvoort T, Zinkstok J, et al. (2006) Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome. Hum Mol Genet 16: 83-91.
28. Meng J, Shi Y, Zhao X, Guo S, Wang H, et al. (2007) No association between the genetic polymorphisms in the RTN4R gene and schizophrenia in the Chinese population. J Neural Transm 114: 249-254.
29. Fallin MD, Belmonte P, Lasseter VK, Cheng N, Avramopoulos D, et al. (2006) Examination of sex and age of onset as important sources of variation for genetic association findings in schizophrenia. Abstract #2076 ASHG Meeting.
30. Pierce T, Bray N, Williams N, Ivanov D, Owen M, et al. (2006) Support for reticulon 4 (Rtn4) as a potential susceptibility gene for schizophrenia. XIV World Congress on Psychiatric Genetics: 179.
31. Sinibaldi L, De Luca A, Bellacchio E, Conti E, Pasini A, et al. (2004) Mutations of the Nogo-66 receptor (RTN4R) gene in schizophrenia. Hum Mutat 24: 534-535.
32. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, et al. (2001) Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 98: 4746-4751.
33. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, et al. (2003) Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362: 798-805.
34. Novak G, Kim D, Seeman P, Tallerico T (2002) Schizophrenia and Nogo: elevated mRNA in cortex, and high prevalence of a homozygous CAA insert. Brain Res Mol Brain Res 107: 183-189.
35. Fournier AE, Gould GC, Liu BP, Strittmatter SM (2002) Truncated soluble Nogo receptor binds Nogo-66 and blocks inhibition of axon growth by myelin. J Neurosci 22: 8876-8883.
36. Wang KC, Kim JA, Sivasankaran R, Segal R, He Z (2002) P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG, and OMgp. Nature 420: 74-78.
37. Barton WA, Liu BP, Tzvetkova D, Jeffrey PD, Fournier AE, et al. (2003) Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins. EMBO J 22: 3291-3302.
38. He XL, Bazan JF, McDermott G, Park JB, Wang K, et al. (2003) Structure of the Nogo receptor ectodomain: a recognition module implicated in myelin inhibition. Neuron 38: 177-185.
39. Keen-Kim D, Mathews CA, Reus VI, Lowe TL, Herrera LD, et al. (2006) Overrepresentation of rare variants in a specific ethnic group may confuse interpretation of association analyses. Hum Mol Genet 15: 3324-3328.
40. Arguello PA, Gogos JA (2006) Modeling Madness in mice: one piece at a time. Neuron 52: 179-196.
41. Puech A, Saint-Jore B, Funke B, Gilbert DJ, Sirotkin H, et al. (1997) Comparative mapping of the human 22q11.2 chromosomal region and the orthologous region in mice reveals complex changes in gene organization. Proc Natl Acad Sci USA 94: 14608-14613.
42. Olson EN, Arnold HH, Rigby PW, Wold BJ (1996) Know your neighbors: three phenotypes in null mutants of the myogenic bHLH gene MRF4. Cell 85: 1-4.
43. Gogos JA, Santha M, Takacs Z, Beck KD, Luine V, et al. (1999) The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat Genet 21: 434-439.
44. Paylor R, Crawley JN (1997) Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology (Berl) 132: 169-180.
45. Phillips RG, LeDoux JE (1992) Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106: 274-285.
46. 2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci 24: 10117-10127.
47. Dudchenko PA (2004) An overview of the tasks used to test working memory in rodents. Neurosci Biobehav Rev 28: 699-709.
48. Baddeley A (1992) Working memory. Science 255: 556-559.
49. Cannon TD, Huttunen MO, Lonnqvist J, Tuulio-Henriksson A, Pirkola T, et al. (2000) The inheritance of neuropsychological dysfunction in twins discordant for schizophrenia. Amer J Hum Genet 67: 369-382.
50. Elvevag B, Goldberg TE (2000) Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14: 1-21.
51. Ellenbroek BA, Cools AR (2000) Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 11: 223-233.
52. Porsolt RD (2000) Animal models of depression: utility for transgenic research. Rev Neurosci 11: 53-58.
53. Cryan JF, Mombereau C, Vassout A (2005) The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29: 571-625.
54. McGee AW, Yang Y, Fischer QS, Daw NW, Strittmatter SM (2005) Experience-driven plasticity of visual cortex limited by myelin and Nogo receptor. Science 309: 2222-2226.
55. Stefani MR, Moghaddam B (2005) Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol Psychiatry 67: 433-436.
56. Harris LW, Sharp T, Gartlon J, Jones DN, Harrison PJ (2003) Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. Eur J Neurosci 18: 1706-1710.
57. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, et al. (1999) Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain. Science 283: 70-74.
58. Colonnese MT, Constantine-Paton M (2006) Developmental period for N-methyl-D-aspartate (NMDA) receptor-dependent synapse elimination correlated with visuotopic map refinement. J Comp Neurol 494: 738-751.
59. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, et al. (2003) White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 60: 443-456.
60. Mitchell AA, Chakravarti A, Cutler DJ (2005) On the probability that a novel variant is a disease-causing mutation. Genome Res 15: 960-966.
61. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, et al. (2004) Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305: 869-872.
62. Altshuler D, Hirschhorn JN (2005) MEF2A sequence variants and coronary artery disease: a change of heart? J Clin Invest 115: 831-833.
63. Abelson JF, Kwan KY, O'Roak BJ, Back DY, Stillman AA, et al. (2005) Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 310: 317-320.
64. Kim JE, Liu BP, Park JH, Strittmatter SM (2004) Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury. Neuron 44: 439-451.
65. Lee LJ, Iwasato T, Itohara S, Erzurumhu RS (2005) Exuberant thalamocortical axon arborization in cortex-specific NMDAR1 knockout mice. J Comp Neurol 485: 280-292.
66. Franks KM, Isaacson JS (2005) Synapse-specific downregulation of NMDA receptors by early experience: a critical period for plasticity of sensory input to olfactory cortex. Neuron 47: 101-114.
67. Manschreck TC, Ames D (1984) Neurologic features and psychopathology in schizophrenic disorders. Biol Psychiatry 19: 703-719.
68. Putzhammer A, Klein HE (2006) Quantitative analysis of motor disturbances in schizophrenic patients. Dialogues Clin Neurosci 8: 123-130.
69. Shprintzen RJ (2006) Velo-cardio-facial syndrome: a distinctive behavioral phenotype. Ment Retard Dev Disabil Res Rev 4: 1142-147.
70. Sobin C, Monk SH, Kiley-Brabeck K, Khuri J, Karayiorgou M (2006) Neuromotor deficits in children with the 22q1.1 deletion syndrome. Mov Disord 21: 2082-2089.
71. Chow EW, Watson M, Young DA, Bassett AS (2006) Neurocognitive profile in 22q11 deletion syndrome and schizophrenia. Schizophr Res 87: 270-278.
72. Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-, et al. (1994) Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 51: 849-859.
73. American Psychiatric Association (1994) DSM-IV: diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Press.
74. Karayiorgou M, Torrington M, Abecasis GR, Pretorius H, Robertson B, et al. (2004) Phenotypic characterization and genealogical tracing in an Afrikaner schizophrenia database. Am J Med Genet B 124: 20-28.
75. Cloninger CR (1989) Schizophrenia: genetic etiological factors. In: Kaplan HI, Saddock BJ, eds. Comprehensive textbook of psychiatry, 5th ed. Baltimore: William & Wilkins.
76. Abecasis GR, Burt RA, Hall D, Bochum S, Doheny KF, et al. (2004) Genomewide scan in families with schizophrenia from the founder population of Afrikaners reveals evidence for linkage and uniparental disomy on chromosome 1. Am J Hum Genet 74: 403-417.
77. Bunting M, Bernstein KE, Greer JM, Capecchi MR, Thomas KR (1999) Targeting genes for self-excision in the germ line. Genes Dev 13: 1524-1528.
78. Gogos JA, Osborne J, Nemes A, Mendelsohn M, Axel R (2000) Genetic ablation and restoration of the olfactory topographic map. Cell 103: 609-620.